International Edition
Latest News
Health

Young Adult Insulin Resistance Tied to 50% Higher Midlife ASCVD Risk, Mediated by Metabolic Syndrome

Insulin resistance measured in young adulthood was associated with a 50% higher risk of atherosclerotic cardiovascular disease over the next 35 years, according to a CARDIA cohort analysis published in JACC: Advances. The study tracked 3,622 participants enrolled…

Insulin resistance measured in young adulthood was associated with a 50% higher risk of atherosclerotic cardiovascular disease over the next 35 years, according to a CARDIA cohort analysis published in JACC: Advances.

The study tracked 3,622 participants enrolled in 1985–1986 at ages 18 to 30. Those with a baseline HOMA‑IR score at or above the 75th percentile (≥2.67) faced a risk ratio of 1.50 (95% CI 1.13–2.01) for ASCVD events through year 35, when participants were 53 to 65 years old, MedPage Today reported.

Midlife metabolic syndrome accounted for nearly two‑thirds of that excess risk. At the year‑20 examination, 63.4% of the insulin resistance–ASCVD relationship was mediated through metabolic syndrome (indirect RR 1.29, 95% CI 1.13–1.48).

“These findings have potential implications for early cardiovascular prevention by suggesting that IR in young adulthood may signal an adverse CKM trajectory before conventional cardiometabolic risk factors become fully established,” wrote lead author Chuyue Wu, MD, PhD, of the UCLA Fielding School of Public Health, and colleagues.

An accompanying editorial framed the result as a call for earlier clinical urgency rather than a new laboratory test.

“For current practice, the most important implication is therefore not a new laboratory test. It is a new sense of urgency,” wrote Amier Haidar, MD, MPH, of McGovern Medical School at UTHealth Houston, and Leonardo Roever, MHS, PhD, of the Brazilian Evidence‑Based Health Network.

“Young adulthood is therefore not a cardiovascular waiting room; it is a period when cardiometabolic trajectories are being established,” the editorialists added.

Fasting insulin is not routinely measured in clinical practice, and HOMA‑IR does not perfectly match the gold‑standard hyperinsulinemic‑euglycemic clamp.

The authors also said that metabolic syndrome status was assessed only at year 20 and that residual confounding is possible in an observational design.

“Further research is needed to determine whether HOMA‑IR improves risk prediction beyond routinely measured clinical factors, develop practical approaches for identifying IR when fasting insulin is unavailable, and test whether preventing or delaying progression to MetS reduces subsequent ASCVD risk,” Wu’s group concluded.

About the author: Health Desk

Health Desk at Archynewsy.